EntryPoint Capital LLC Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

EntryPoint Capital LLC acquired a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the 4th quarter, HoldingsChannel reports. The fund acquired 7,804 shares of the biopharmaceutical company’s stock, valued at approximately $256,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. State Street Corp lifted its holdings in Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after buying an additional 216,484 shares during the period. Vestal Point Capital LP bought a new position in shares of Agios Pharmaceuticals during the third quarter worth about $33,767,000. BNP Paribas Financial Markets lifted its stake in shares of Agios Pharmaceuticals by 15.1% in the third quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company’s stock worth $531,000 after acquiring an additional 1,570 shares during the period. FMR LLC boosted its holdings in Agios Pharmaceuticals by 283.2% in the third quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company’s stock valued at $2,017,000 after acquiring an additional 33,546 shares during the last quarter. Finally, Intech Investment Management LLC bought a new stake in Agios Pharmaceuticals in the third quarter valued at approximately $892,000.

Insider Activity at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.93% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Scotiabank boosted their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Royal Bank of Canada boosted their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. HC Wainwright began coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a “buy” rating and a $58.00 price objective for the company. Finally, StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $56.57.

Agios Pharmaceuticals Price Performance

Shares of AGIO opened at $30.28 on Friday. Agios Pharmaceuticals, Inc. has a one year low of $27.14 and a one year high of $62.58. The company has a market cap of $1.73 billion, a PE ratio of 2.67 and a beta of 0.90. The stock has a 50-day moving average of $33.17 and a 200-day moving average of $40.87.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.